A Case-Based Roadmap for Improved Patient Outcomes in Plaque Psoriasis

To participate in this activity, please:

Plaque psoriasis is a chronic inflammatory skin condition that impacts patient physical, social, and emotional well-being. Join Dr. Steven Feldman in an interactive case-based overview of managing patients with plaque psoriasis. Diagnosis, severity assessment, and treatment are discussed to provide clinicians with a broad overview of optimal plaque psoriasis management. Treatment initiation, switching, and escalation are reviewed, with a focus on common clinical scenarios, such as unplanned treatment interruption and selecting agents for patients who intend to conceive.

Course Credit:

1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour

Dates:

Opens: 2021-08-31
Closes: 2022-08-31

Target Audience:

This activity was developed for dermatologists, primary care physicians, nurse practitioners, physician assistants and other healthcare providers who manage patients with plaque psoriasis.

This activity is supported by educational grants from UCB and AbbVie.

    Presenting Faculty

  • Steven R. Feldman, MD, PhD

    Professor of Dermatology, Pathology, and Social Sciences & Health Policy
    Wake Forest University Health Sciences
    Winston-Salem, North Carolina

Learning Objectives

  • Utilize validated tools to assess plaque psoriasis disease burden and response to treatment
  • Summarize the clinical pharmacology, including mechanism of action, as well as safety and efficacy, of evidence-based medications for plaque psoriasis
  • Apply the results of clinical trials, expert recommendations, and consensus guidelines to develop treatment plans based on patient characteristics, treatment history, and comorbid conditions

Faculty Disclosures

Steven R. Feldman, MD, PhD

Chief Technology Officer: Causa Technologies

Consultant: AbbVie, Advance Medical, Almirall, Alvotech, Amgen, Arcutis, Arena, BMS, Caremark, Celgene, Dermavant, Galderma Laboratories, LP, Gerson, Lehrman Group, Guidepoint Global, Helsinn, Janssen, Kikaku, Leo Pharma Inc, Lilly, Merck & Co, Inc, Mylan, Novartis Pharmaceuticals Corporation, Ortho Dermatology, Pfizer Inc, Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, XenoPort

Founder: Causa Technologies

Grant Support: AbbVie, Amgen, Celgene, Galderma Laboratories, LP, Janssen, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron, Sanofi

Royalties: Informa, UpToDate, Xlibris

Speakers Bureau: AbbVie, Amgen, Celgene, Janssen, Leo Pharma Inc, Lilly, Novartis      Pharmaceuticals Corporation, Ortho Dermatology, Pfizer Inc, Regeneron, Sanofi, Sun Pharma

Stockholder: Causa Technologies, Medical Quality Enhancement Corporation


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.00 contact hour may be earned for successful completion of this activity.

Additional Content Planners

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Jessica Martin, PhD (Medical Writer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.